Oncologic Confirmatory Trial Accrual Is Part Of FDA-EMEA Agreement
Executive Summary
FDA will share information with the European Medicines Agency to ensure that EMEA's new "conditional" approval program will not negatively impact completion of confirmatory trials for products receiving U.S. accelerated approval, Office of Oncology Drug Products Director Richard Pazdur said